Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
 - Shares are not adjusted for stock split.
 
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
 - Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date  | Reported DateTime  | Company | Symbol | Insider Relationship  | Shares Traded  | Average Price  | Total Amount  | Shares Owned  | Filing | 
| 2025-09-15 Purchase  | 2025-09-17 5:22 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 660 | $23.7 | $15,639 | 6,829,524 (Indirect)  | View | 
| 2025-09-09 Sale  | 2025-09-10 5:39 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 150,000 | $25.83 | $3,874,017 | 295,015 (Direct)  | View | 
| 2025-09-08 Purchase  | 2025-09-10 5:19 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 1,260 | $24.99 | $31,487 | 6,828,864 (Indirect)  | View | 
| 2025-09-03 Sale  | 2025-09-05 5:06 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 18,073 | $25.09 | $453,452 | 15,000 (Direct)  | View | 
| 2025-08-25 Sale  | 2025-08-27 5:08 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 8,269 | $24.86 | $205,567 | 15,000 (Direct)  | View | 
| 2025-08-21 Sale  | 2025-08-25 5:04 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer  | 100,000 | $24.72 | $2,471,640 | 69,302 (Indirect)  | View | 
| 2025-08-11 Purchase  | 2025-08-13 4:49 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 471 | $23.98 | $11,294 | 6,827,604 (Indirect)  | View | 
| 2025-07-15 Sale  | 2025-07-17 5:19 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 98,612 | $21.26 | $2,096,655 | 420,447 (Direct)  | View | 
| 2025-06-24 Purchase  | 2025-06-26 7:41 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 3,780 | $18.38 | $69,466 | 6,827,133 (Indirect)  | View | 
| 2025-06-16 Sale  | 2025-06-18 4:50 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $19.29 | $1,929,141 | 678,143 (Direct)  | View | 
| 2025-06-16 Purchase  | 2025-06-18 4:42 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 8,584 | $19.5 | $167,381 | 6,823,153 (Indirect)  | View | 
| 2025-05-15 Sale  | 2025-05-19 4:44 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | $0 | 494,930 (Direct)  | View | 
| 2025-04-15 Sale  | 2025-04-17 5:41 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | $0 | 594,930 (Direct)  | View | 
| 2025-03-26 Purchase  | 2025-03-28 5:36 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 1,135 | $22.49 | $25,521 | 6,814,569 (Indirect)  | View | 
| 2025-03-26 Sale  | 2025-03-28 5:18 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 16,539 | $0 | $0 | 60,539 (Direct)  | View | 
| 2025-03-26 Sale  | 2025-03-28 5:15 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer  | 12,258 | $0 | $0 | 428,835 (Direct)  | View | 
| 2025-03-17 Sale  | 2025-03-19 5:29 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | $0 | 742,181 (Direct)  | View | 
| 2025-03-04 Purchase  | 2025-03-06 5:32 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Topper James N Director  | 4,005 | $21.02 | $84,203 | 6,813,434 (Indirect)  | View | 
| 2025-03-04 Sale  | 2025-03-05 6:10 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 150,000 | $20.37 | $3,055,500 | 33,073 (Direct)  | View | 
| 2025-02-18 Sale  | 2025-02-20 5:24 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | $0 | 305,508 (Direct)  | View | 
| 2025-01-29 Sale  | 2025-01-31 5:00 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 70,441 | $0 | $0 | 509,868 (Direct)  | View | 
| 2025-01-27 Sale  | 2025-01-29 5:25 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer  | 61,883 | $0 | $0 | 1,578,528 (Direct)  | View | 
| 2025-01-27 Sale  | 2025-01-29 5:16 pm  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 129,559 | $0 | $0 | 662,557 (Direct)  | View | 
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date  | Reported DateTime  | Exercisable Expiration  | Company | Symnbol | Insider Relationship  | Shares Traded  | Conversion Price  | Shares Owned  | Filing | 
| 2025-09-09 Exercise  | 2025-09-10 5:39 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 150,000 | $10 | 295,015 (Direct)  | View | 
| 2025-09-09 Exercise  | 2025-09-10 5:39 pm  | N/A 2032-11-22  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 150,000 | $0 | 295,015 (Direct)  | View | 
| 2025-09-02 Exercise  | 2025-09-04 5:43 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 18,073 | $0 | 33,073 (Direct)  | View | 
| 2025-07-15 Exercise  | 2025-07-17 5:19 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 98,612 | $10.9 | 420,447 (Direct)  | View | 
| 2025-07-15 Exercise  | 2025-07-17 5:19 pm  | N/A 2033-01-01  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 98,612 | $0 | 420,447 (Direct)  | View | 
| 2025-06-16 Exercise  | 2025-06-18 4:50 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 78,101 | $10 | 678,143 (Direct)  | View | 
| 2025-06-16 Exercise  | 2025-06-18 4:50 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 21,899 | $10.9 | 678,143 (Direct)  | View | 
| 2025-06-16 Exercise  | 2025-06-18 4:50 pm  | N/A 2032-11-22  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | 678,143 (Direct)  | View | 
| 2025-06-01 Option Award  | 2025-06-03 5:02 pm  | N/A 2035-06-01  | NewAmsterdam Pharma Co N.V. | NAMS | Marino Michael F III See Remarks  | 370,000 | $0 | 370,000 (Direct)  | View | 
| 2025-06-01 Exercise  | 2025-06-03 4:59 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director  | 68 | $0 | 28,186 (Direct)  | View | 
| 2025-05-15 Exercise  | 2025-05-19 4:44 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $10 | 494,930 (Direct)  | View | 
| 2025-05-15 Exercise  | 2025-05-19 4:44 pm  | N/A 2032-11-22  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | 494,930 (Direct)  | View | 
| 2025-05-01 Option Award  | 2025-05-02 4:56 pm  | N/A 2035-05-01  | NewAmsterdam Pharma Co N.V. | NAMS | Audet Juliette Berangere See Remarks  | 30,000 | $0 | 30,000 (Direct)  | View | 
| 2025-05-01 Exercise  | 2025-05-02 4:55 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director  | 69 | $0 | 28,186 (Direct)  | View | 
| 2025-04-14 Exercise  | 2025-04-21 5:41 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director  | 69 | $0 | 28,186 (Direct)  | View | 
| 2025-04-15 Exercise  | 2025-04-17 5:41 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $10 | 594,930 (Direct)  | View | 
| 2025-04-15 Exercise  | 2025-04-17 5:41 pm  | N/A 2032-11-22  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | 594,930 (Direct)  | View | 
| 2025-04-15 Option Award  | 2025-04-17 5:36 pm  | N/A 2035-04-15  | NewAmsterdam Pharma Co N.V. | NAMS | Gulfo Adele M. Director  | 61,560 | $0 | 61,560 (Direct)  | View | 
| 2025-03-26 Option Award  | 2025-03-28 5:29 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 8,269 | $0 | 31,538 (Direct)  | View | 
| 2025-03-26 Exercise  | 2025-03-28 5:29 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 8,269 | $0 | 31,538 (Direct)  | View | 
| 2025-03-26 Option Award  | 2025-03-28 5:24 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director  | 3,308 | $0 | 13,576 (Direct)  | View | 
| 2025-03-26 Exercise  | 2025-03-28 5:24 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | LANGE LOUIS G Director  | 3,102 | $0 | 13,576 (Direct)  | View | 
| 2025-03-26 Option Award  | 2025-03-28 5:20 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer  | 64,783 | $0 | 294,264 (Direct)  | View | 
| 2025-03-26 Exercise  | 2025-03-28 5:20 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer  | 45,481 | $0 | 294,264 (Direct)  | View | 
| 2025-03-26 Option Award  | 2025-03-28 5:18 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 16,539 | $0 | 60,539 (Direct)  | View | 
| 2025-03-26 Exercise  | 2025-03-28 5:18 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 16,539 | $0 | 60,539 (Direct)  | View | 
| 2025-03-26 Option Award  | 2025-03-28 5:15 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer  | 69,386 | $0 | 428,835 (Direct)  | View | 
| 2025-03-26 Exercise  | 2025-03-28 5:15 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Davidson Michael H. Chief Executive Officer  | 38,394 | $0 | 428,835 (Direct)  | View | 
| 2025-03-24 Exercise  | 2025-03-26 4:27 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kastelein Johannes Jacob Pieter Chief Scientific Officer  | 150,000 | $0 | 970,229 (Indirect)  | View | 
| 2025-03-17 Exercise  | 2025-03-19 5:29 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 11,888 | $10 | 742,181 (Direct)  | View | 
| 2025-03-17 Exercise  | 2025-03-19 5:29 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | 742,181 (Direct)  | View | 
| 2025-03-04 Exercise  | 2025-03-05 6:10 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kooij Louise Frederika Chief Accounting Officer  | 150,000 | $0 | 33,073 (Direct)  | View | 
| 2025-02-18 Exercise  | 2025-02-20 5:24 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 100,000 | $0 | 305,508 (Direct)  | View | 
| 2025-01-29 Exercise  | 2025-01-31 5:00 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 70,441 | $0 | 509,868 (Direct)  | View | 
| 2025-01-27 Exercise  | 2025-01-29 5:25 pm  | N/A 2033-11-01  | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer  | 61,883 | $0 | 1,578,528 (Direct)  | View | 
| 2025-01-27 Exercise  | 2025-01-29 5:25 pm  | N/A N/A  | NewAmsterdam Pharma Co N.V. | NAMS | Somaiya Mayur Ian Chief Financial Officer  | 61,883 | $9.26 | 1,578,528 (Direct)  | View | 
| 2025-01-27 Exercise  | 2025-01-29 5:16 pm  | N/A 2031-07-06  | NewAmsterdam Pharma Co N.V. | NAMS | Kling Douglas F Chief Operating Officer  | 129,559 | $0 | 662,557 (Direct)  | View | 
| 2025-01-06 Option Award  | 2025-01-08 6:09 pm  | N/A 2035-01-06  | NewAmsterdam Pharma Co N.V. | NAMS | Smither John W Director  | 39,460 | $0 | 39,460 (Direct)  | View | 
| 2025-01-06 Option Award  | 2025-01-08 6:08 pm  | N/A 2035-01-06  | NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director  | 39,460 | $0 | 39,460 (Direct)  | View | 
| 2025-01-06 Option Award  | 2025-01-08 6:03 pm  | N/A 2035-01-06  | NewAmsterdam Pharma Co N.V. | NAMS | Lewis William Director  | 39,460 | $0 | 39,460 (Direct)  | View | 
| 2025-01-06 Option Award  | 2025-01-08 5:58 pm  | N/A 2035-01-06  | NewAmsterdam Pharma Co N.V. | NAMS | van der Kamp Hilde Johanna Director  | 39,460 | $0 | 39,460 (Direct)  | View |